Pharmacodynamic Interactions

PD Interactions Intro - Dynamic Duos & Duels

• PD interactions: Drugs modify each other's effects at common target sites (e.g., receptors, enzymes, ion channels, signal transduction pathways).

  ⭐ Pharmacodynamic interactions involve modification of drug effect without change in its concentration at the site of action.

• Dynamic Duos (Synergism): Combined effect is enhanced.
  • Additive: $Effect_A + Effect_B = Combined Effect$ (e.g., Aspirin + Paracetamol for analgesia).
  • Supra-additive (Potentiation): $Combined Effect > Effect_A + Effect_B$ (e.g., Levodopa + Carbidopa).
• Dynamic Duels (Antagonism): One drug reduces or nullifies another's effect (e.g., Naloxone + Morphine).

Synergism Spotlight - Power-Up Combos

• Definition: Combined drug effect > sum of individual effects ($1+1 > 2$).
• Key Mechanisms & Examples:
  • Sequential Blockade: Drugs block sequential steps in a pathway.

    ⭐ Co-trimoxazole (Sulfamethoxazole + Trimethoprim) achieves synergism via sequential blockade of microbial folic acid synthesis.

  • Enhanced Drug Uptake: One drug aids another's cell entry.
    • E.g., Penicillins + Aminoglycosides (cell wall damage ↑ entry).
  • Different Mechanisms, Same Effect: Distinct actions, common outcome.
    • E.g., Aspirin + Clopidogrel (varied antiplatelet pathways).
    • E.g., ACE inhibitors + Thiazides (antihypertensive).
  • Receptor Level Synergism: Same/related receptor action.
    • E.g., Benzodiazepines + Alcohol (↑ GABA; ⚠️ CNS depression). oka

Antagonism Explained - Effect Blockers

Antagonism: One drug diminishes or abolishes another's effect. (8)

• Pharmacological Antagonism: Antagonist blocks agonist at its receptor. (8)
  • Competitive:
    • Reversibly binds same agonist site. (5)
    • Shifts agonist Dose-Response Curve (DRC) right. (7)
    • Maximal effect ($E_{max}$) unchanged; overcome by ↑ agonist. (9)
    • E.g., Naloxone + Morphine. (4)
  • Non-Competitive:
    • Binds allosteric site or irreversibly to active site. (9)
    • ↓ Agonist $E_{max}$; not overcome by ↑ agonist. (9)
    • DRC flattened, may shift right. (6)
    • E.g., Ketamine (NMDA receptor). (4)
• Physiological (Functional) Antagonism:
  • Two drugs, different receptors/pathways, opposing physiological effects. (9)
  • E.g., Histamine (bronchoconstriction) vs. Adrenaline (bronchodilation). (7)
• Chemical Antagonism:
  • Direct chemical interaction inactivates one drug. (7)
  • E.g., Chelating agents (Dimercaprol) + heavy metals. (7)

⭐ Naloxone is a pure opioid antagonist with high affinity for μ-receptors, rapidly reversing opioid overdose effects. (20)

Pharmacodynamic Antagonism Types: (3)

Clinical Impact - Patient Safety Alerts

• Synergistic Toxicity: Potentially severe adverse outcomes.
  • CNS depression: Benzodiazepines + Opioids/Alcohol.
  • Bleeding risk: Warfarin + Aspirin/NSAIDs.
  • Serotonin Syndrome: SSRIs + MAOIs/Triptans. ⚠️
  • QT Prolongation: Multiple QT-prolonging drugs (e.g., Macrolides, Antifungals, Antipsychotics).
  • Severe Hypotension: Multiple antihypertensives.
  • ↑ Hyperkalemia: ACE inhibitors + K-sparing diuretics.
  • Hypertensive Crisis: MAOIs + Tyramine-rich foods.

  ⭐ Combining sildenafil with nitrates can cause severe, potentially fatal hypotension due to synergistic effects on cGMP.

• Antagonistic Effects: Can lead to therapeutic failure.
  • ↓ Therapeutic efficacy: NSAIDs + ACE inhibitors (↓ renal protection, ↓BP control).
  • ↓ Bronchodilation: β-blockers + Salbutamol (e.g., Propranolol + Salbutamol).
• General Risks & Management:
  • Narrow Therapeutic Index (NTI) drugs (e.g., Digoxin, Warfarin, Lithium) pose higher risk.
  • Polypharmacy, elderly, renal/hepatic impairment ↑ vulnerability.
  • Crucial: Medication review, patient education, monitoring for ADRs.

High‑Yield Points - ⚡ Biggest Takeaways

• Pharmacodynamic interactions alter drug response without changing plasma levels.
• Synergism (1+1 > 2, e.g., TMP-SMX) vs. Additive (1+1 = 2, e.g., Aspirin + Paracetamol).
• Competitive antagonists shift Dose-Response Curve (DRC) right; Non-competitive antagonists ↓ Emax.
• Physiological antagonism: Different receptors, opposing actions (e.g., Adrenaline & Histamine).
• Potentiation: One drug (often inactive) enhances another (e.g., Levodopa + Carbidopa).
• Key examples: Serotonin Syndrome (SSRIs + MAOIs), Digoxin toxicity with hypokalemia induced by diuretics.